A judge threw out Angelina Jolie’s motions to dismiss Brad Pitt’s lawsuit over their French vineyard — a major victory for the A-lister that could pave the way for the former couple’s ...
Angelina Jolie, who’s gearing up for the nationwide release of her biopic Maria, has mostly declined the opportunity to method dress as Maria Callas. But that didn’t stop the actress from ...
A source close to Brad Pitt tells PEOPLE the court ruling "is a clear victory for Brad" in his lawsuit against Angelina Jolie over a French winery they co-owned Bruce Glikas/Getty; Jon Kopaloff ...
How Angelina Jolie moved “Maria” director to tears by 'burning herself' raw with emotion (exclusive)
EW has an exclusive preview of the new Maria Callas drama, with Pablo Larraín recalling the moment Jolie's work pushed him to the emotional brink. He praises Jolie, already an Oscar-winning ...
Her work has previously appeared in The Zoe Report, Popsugar, Insider and more. Angelina Jolie is an icon in more ways than one. The award-winning actress has teamed up with Tom Ford Beauty yet ...
Long before the term quiet luxury entered the fashion vernacular, Hollywood's most haute actress Angelina Jolie was schooling us in elevated, minimalistic dressing for every occasion.
The star pays "cinematic homage to feminine beauty and its power" in the new campaign for Tom Ford's Runway Lip Color Angelina Jolie is an icon in more ways than one. The award-winning actress has ...
The US Food and Drug Administration (FDA) has accepted for review the resubmitted supplemental Biologics License Application (sBLA) for Sanofi and Regeneron’s Dupixent (dupilumab) in chronic ...
The FDA decision is expected by April 18, 2025. If approved, Dupixent would be the first targeted therapy for CSU in a decade. The sBLA for Dupixent (dupilumab) is to treat adults and pediatric ...
The BOREAS Phase III trial showed DUPIXENT reduced exacerbations by 30% and improved lung function by 160 mL at 52 weeks. Approximately 44 million COPD cases were recorded in 2023 in the 7MM ...
Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License Application, or sBLA, for Dupixent to treat adults and ...
Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in CSU, which causes sudden and debilitating hives and recurring itch. The companies said an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback